Carcinoma, Pancreatic Ductal Clinical Trial
Official title:
Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer
In recent years, treatment of advanced pancreatic cancer is changing. Currently, there are several active schedules of chemotherapy that can be used, such as gemcitabine as monotherapy or in combination with capecitabine or erlotinib, and FOLFIRINOX. Moreover, the development of biomarker (therapeutic targets) that can predicte response to treatment is a new important tool to be used in clinical practice to select the best scheme for each patient. Preliminary studies showed that therapeutic target determination, using tumor tissue collected from patients, could determine the presence of groups of "chemotherapy responders". Such is the case of EGFR amplification and/or K-Ras gene status and correlation with response to erlotinib. Moreover, Thymidilate Synthase, Thimidine Phosphorylase, ERCC-1 and Topoisomerase I expression by immunohistochemistry in GI tumor samples has been related to resistance or response to 5FU-capecitabine, oxaliplatin and irinotecan respectively. Based on this data the investigators designed a phase II clinical trial to evaluate the efficacy of selected treatment for pancreatic cancer patients based on the determination of therapeutic targets. The therapeutic target-driven treatment efficacy will be compared to the prospective treatment of a control group of patients treated at the discretion of the physician-researcher
Study Phase: Phase 2 Trial
Study Objetives:
- Primary end-point. Proportion of patients alive after 12 months in patients with
advanced pancreatic carcinoma individually selected and grouped according to the
expression in tumor tissue for therapeutic targets.
- Secondary end-points. 1. Assessing the feasibility of the method of
patient-treatment-selection based on tumor tissue expression of therapeutic targets. 2.
Overal survival comparison between Gemcitabine single agent treatment and the rest of
chemotherapy schedules. 3. Determination of progression-free survival for each
treatment group. 4. Determination of toxicity in all the patients.
Study population and Number of subject: A total of 60 pancreatic cancer patients with
advanced pancreas cancer with no previous systemic treatment are expected to be enrolled.
Study design and schedule. Patients will be randomized (1:1) to a control arm or an
experimental treatment arm guided by therapeutic targets. In the control arm, patients are
treated with conventional chemotherapy regimens at the discretion of the investigator. In
the experimental arm, patients are treated as determined in tumor tissue available for
biomarker TS, TP, ERCC-1, Topo-1, K-Ras mutation and EGFR FISH, choosing FOLFIRINOX schemas,
FOLFOX, FOLFIRI, Gemcitabine-Capecitabine Gemcitabine-Erlotinib, Gemcitabine single agent.
All patients will be analyzed by intention to treat
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03500068 -
Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.
|
N/A | |
| Not yet recruiting |
NCT05489458 -
Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
|
||
| Recruiting |
NCT02310230 -
An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy
|
N/A | |
| Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03513705 -
Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)
|
N/A | |
| Completed |
NCT01808638 -
Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00226746 -
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03432624 -
Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT02529579 -
Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02451384 -
According CTC to Compare the Influences of Different Methods to Remove the PDAC
|
N/A | |
| Not yet recruiting |
NCT06447662 -
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
|
Phase 1 | |
| Recruiting |
NCT02817308 -
Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas
|
N/A | |
| Completed |
NCT00471146 -
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
|
Phase 3 | |
| Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
| Terminated |
NCT01413451 -
Amatuximab for High Mesothelin Cancers
|
Early Phase 1 | |
| Recruiting |
NCT03403101 -
The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT02928081 -
Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma
|
N/A | |
| Completed |
NCT05723978 -
Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
|
||
| Completed |
NCT02150746 -
Circulating Tumor Cells in Operative Blood
|
N/A | |
| Completed |
NCT04146441 -
Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma
|
Phase 2 |